Inhibikase Therapeutics, Inc. (NasdaqCM: IKT)
Health Care · Biotechnology · US
$1.85
-6.35% today · +20.9% 1Y
Inhibikase Therapeutics, Inc. (NasdaqCM: IKT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $358.69M and employs 35 people.
Over the last twelve months the share price has gained 20.9%, trading between 1.33 and 2.61.
Tweenvest scores Inhibikase Therapeutics, Inc. across four factors: quality 53/100, value 75/100. Its strongest factor is value.
IKT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $358.69M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.43
- Dividend yield
- —
- Beta (5Y)
- 0.90
- 52-week high
- $2.61
- 52-week low
- $1.33
- Avg volume (3M)
- —
- Shares outstanding
- 182.07M
- Employees
- 35
- Next earnings
- —
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
- ISIN
- US45719W2052
- Founded
- 2008
- Listed since
- Dec 23, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Fennec Pharmaceuticals Inc.NasdaqCM: FENC | $375.57M | $10.72 | +0.09% |
| Hansa Biopharma AB (publ)OM: HNSA | $365.97M | Skr36.12 | +0.44% |
| ProKidney Corp.NasdaqCM: PROK | $363.53M | $1.67 | -4.02% |
| PureTech Health plcLSE: PRTC | $360.13M | £1.13 | +1.44% |
| Enanta Pharmaceuticals, Inc.NasdaqGS: ENTA | $358.24M | $12.30 | -1.60% |
| Emergent BioSolutions Inc.NYSE: EBS | $357.89M | $6.98 | -1.13% |
| Cuorips Inc.TSE: 4894 | $353.89M | ¥6,310.00 | +0.80% |
| Jiangsu CoWin Biotech Co., Ltd.SHSE: 688426 | $353.03M | CN¥21.51 | -4.74% |
Figures last refreshed Oct 11, 2026.